

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

NCT05190991

Status	RECRUITING
Phase	Phase 2
Sponsor	R-Pharm International, LLC
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (30)

- The patient with Familial Mediterranean Fever (FMF) with resistance to or intolerance of colchicine, who completed the core study, during which he/she received at least one dose of RPH-104.
 - Voluntarily signed and dated Patient Informed Consent Form (ICF) for participation in this study.
 - The patient's ability and desire, according to the Investigator's discretion, to follow the schedule of visits, follow the study procedures and follow the Protocol requirements, including the following:
 - to visit the study site every 2 weeks for RPH-104 administration by qualified study site personnel
 - or
- ... and 25 more (see full listing online)

Locations (8 total)

Center of Medical Genetics and Primary Health Care LLC, Yerevan, Armenia
FSBEI HE First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia
Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin, Moscow, Russia
... and 5 more locations